Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal
Executive Summary
Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense
You may also be interested in...
Genasense AC review
Genta's chronic lymphocytic leukemia treatment Genasense will be reviewed by FDA's Oncologic Drugs Advisory Committee Sept. 6, the company said. The oblimersen injection plus chemotherapy regimen is currently pending at FDA under a standard review, with an Oct. 29 user fee date. Genta initially sought a melanoma indication, but withdrew the NDA in May 2004 following a negative advisory committee review (1"The Pink Sheet" May 24, 2004, p. 12)...
Genasense AC review
Genta's chronic lymphocytic leukemia treatment Genasense will be reviewed by FDA's Oncologic Drugs Advisory Committee Sept. 6, the company said. The oblimersen injection plus chemotherapy regimen is currently pending at FDA under a standard review, with an Oct. 29 user fee date. Genta initially sought a melanoma indication, but withdrew the NDA in May 2004 following a negative advisory committee review (1"The Pink Sheet" May 24, 2004, p. 12)...
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers